[Efficacy and tolerability of acyclovir in immunosuppressed patients with herpes simplex, herpes zoster or cutaneomucous chicken-pox. Multicenter trial apropos of 50 cases].
A multicenter trial of Acyclovir was carried out in 50 immunodepressed patients. The dose used was 15 mg/kg/day for 5 days in herpes simplex and 30 mg/kg/day for 10 days in herpes zoster and chicken pox by three one-hourly intravenous infusion per day. Acyclovir had a clear cut effect in 42 cases, a partial effect in 1 case, no effect in 1 case, and its action could not be assessed in 6 cases. The cutaneous and mucous membrane lesions were stabilised after an average of two days' treatment, and regression was observed from the third day. Of the 21 cases of zoster, 15 were cured without sequellae and 5 with post-zoster pain. The treatment failed in one patient. Of the 21 cases of cutaneous and/or mucous membrane herpes simplex, 20 satisfactory and 1 partial result were obtained. The outcomes of the 2 cases of chicken pox were favourable. There were three relapses after the end of therapy (2 herpes simplex, 1 zoster) but their outcomes were favourable after a second course of Acyclovir. In 20 cases it was possible to maintain the immuno-suppressive therapy. General tolerance was satisfactory.
D000212:Acyclovir / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002644:Chickenpox / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy* / Q000276:immunology; D006562:Herpes Zoster / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011379:Prognosis
D000212:Acyclovir
Efficacité et tolérance de l'acyclovir chez l'immunodéprimé atteint d'herpès, de zona ou de varicelle cutanéo-muqueux. Essai multicentrique à propos de 50 observations.